Homocysteine and Atherosclerosis: Have We Been Targeting the Wrong Molecule?

Scientists are continually uncovering new pathways that influence the initiation and propagation of atherosclerosis. Among these pathways are pathways involving molecules such as GGT and homocysteine.
The pathways of interest influence the formation of atherosclerotic plaque and can ultimately influence the development of cardiovascular disease, including ischemic stroke.
Homocysteine and Atherosclerosis
The role of homocysteine as one of these processes is still being examined, and research in the pathophysiology of homocysteine is currently ongoing. Although the association between elevated homocysteine and cardiovascular disease has been recognized for decades, researchers are still investigating the precise mechanisms by which homocysteine and its metabolites may contribute to vascular injury. Nevertheless, we have unearthed several mechanisms by which homocysteine may influence atherogenesis. These pathways often initiate endothelial dysfunction, an essential precursor in the formation of atherosclerotic plaque.
Homocysteine and Cellular Methylation
Homocysteine is formed from the essential amino acid methionine. Methionine is converted into AdoMet when an adenosyl group from ATP is transferred to methionine. AdoMet serves as the principal methyl-group donor in numerous biological methylation reactions. AdoMet, however, is transformed to S-adenosylhomocysteine (AdoHcy) after donating a methyl group to other molecules in the body. The resulting S-adenosylhomocysteine (AdoHcy), however, is a potent inhibitor of many methyltransferases. Consequently, the balance between AdoMet and AdoHcy helps determine the methylation potential of the cell.
Normally, AdoHcy is hydrolyzed to homocysteine and adenosine. However, this reaction is reversible. Consequently, accumulation of homocysteine can favor the accumulation of AdoHcy. Accumulation of AdoHcy can disrupt normal methylation processes, thereby altering gene expression, protein function and numerous cellular regulatory mechanisms. The result is a malfunction of crucial processes in the body across a multitude of systems.
Disruption of Vascular Gasotransmitters
Experimental studies have shown that an accumulation of AdoHcy impairs the formation of NO, which is a potent vasodilator and regulator of endothelial function. At the same time, it stymies the production of another gasotransmitter involved in the regulation of endothelial function, H2S. Like nitric oxide, hydrogen sulfide contributes to vascular relaxation and the maintenance of endothelial integrity. It also possesses anti-inflammatory and antioxidant properties. Reduced hydrogen sulfide availability may therefore favor the expression of endothelial adhesion molecules and inflammatory chemokines.
From Endothelial Dysfunction to Atherosclerosis
Chemokines can recruit monocytes from the circulation that adhere to the vascular endothelium and that can differentiate into macrophages. These macrophages can become infused with oxidized lipids to form foam cells. It is this collection of foam cells and other cellular debris that forms the foundation of atherosclerotic plaque and leads to plaque instability and rupture.
The accumulation of lipid-laden macrophages, the foam cells, contributes to the formation and progression of atherosclerotic plaque. As the inflammatory process continues, cellular death and the accumulation of debris can promote the formation of a necrotic core and weaken the fibrous cap covering the plaque. Rupture or erosion of susceptible plaques can precipitate thrombosis, leading to acute myocardial infarction or certain forms of ischemic stroke.
Homocysteine and Oxidative Stress
Besides this activation of the endothelium through the increased expression of adhesion molecules and chemokines, AdoHcy can disrupt the redox system operating in the vessel wall. Homocysteine can be metabolized in the body by either of two pathways. Either it is reconverted back to methionine by remethylation, or it is converted to cysteine by transsulfuration. It is this trans-sulfuration pathway that is involved in the production of potent antioxidants such as glutathione in the body.
The transsulfuration pathway involves two principal enzymes:
Cystathionine beta-synthase (CBS): Converts homocysteine and serine into cystathionine.
Cystathionine gamma-lyase (CSE): Converts cystathionine into cysteine.
Both enzymes require vitamin B6 in its active form, pyridoxal phosphate.
Cysteine is subsequently available for the synthesis of glutathione, a major intracellular antioxidant.
When these systems are disrupted, reactive oxygen species, ROS, can damage proteins and cells in the circulation and vessel wall. One of the byproducts of oxidative stress is oxidized LDL. Oxidized LDL is easily taken up by macrophages in the vessel wall to form the aforementioned foam cells. Furthermore, oxidation itself causes direct damage to the endothelial cells.
Homocysteine and Thrombosis
Finally, hyperhomocysteinaemia has also been associated with increased levels of vasoconstrictors such as endothelin-1 and thromboxane A₂. In addition to promoting vasoconstriction, thromboxane A₂ stimulates platelet activation and aggregation, thereby favoring thrombus formation. These changes may further contribute to the prothrombotic environment associated with disturbances in homocysteine metabolism.
Have We Been Targeting the Wrong Molecule?
Despite these proposed mechanisms of endothelial injury, lowering homocysteine through B-vitamin supplementation has yielded disappointing clinical results. Large randomized controlled trials have failed to demonstrate significant reductions in myocardial infarction or overall mortality, although modest reductions in stroke risk have been reported.
One possible explanation is that lower blood homocysteine does not automatically translate into lower intracellular homocysteine or its metabolically important precursor, AdoHcy. That would therefore mean that these pathological processes continue unabated even after homocysteine levels are restored to normal.
Another possible explanation is that damage induced by high homocysteine levels may be permanent, and restoration of physiologic levels does not reverse these changes. Such a scenario would necessitate measures to prevent hyperhomocysteinaemia in the first place.
Alternatively, moderately elevated circulating homocysteine may be more of a marker of metabolic dysfunction than a major independent cause of coronary artery disease.
These observations raise an important question: have we been targeting the wrong molecule?
Future research may need to focus not exclusively on lowering circulating homocysteine, but on restoring the integrity of the metabolic pathways in which homocysteine and its related metabolites participate.


Comments